PFA Technology Poised to Revolutionize Atrial Fibrillation Treatment as Medtronic and Boston Scientific Vie for FDA Approval in Burgeoning Market
-
Pulsed-field ablation (PFA) is an innovative technology with potential to revolutionize atrial fibrillation treatment. Favorable clinical outcomes so far.
-
Medtronic's PulseSelect PFA system received FDA approval on December 13, 2023. Boston Scientific's FARAPULSE expected to follow.
-
Strong uptake of PFA technology already from 2021 European approval of FARAPULSE and 2023 Australian approval.
-
Global PFA market value estimated at $232 million in 2023 with potential to reach $2.9 billion by 2028.
-
Clarivate MedTech Insights reports provide forecasts and analysis of mapping/ablation device markets (US, Europe, Japan, Asia Pacific).